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A B S T R A C T
Sprouty2 (Spry2) acts as a central regulator of tubular growth and branch patterning in the developing mam-
malian lung by controlling both magnitude and duration of growth factor signalling. To determine if this protein
coordinates airway and vascular growth factor signalling, we tested the hypothesis that Spry2 links the primary
cue for airway outgrowth, ﬁbroblast growth factor-10 (FGF-10), to genomic events underpinning the expression
and release of vascular endothelial growth factor-A (VEGF-A). Using primary fetal distal lung epithelial cells
(FDLE) from rat, and immortalised human bronchial epithelial cells (16HBE14o-), we identiﬁed a nuclear sub-
population of Spry2 which interacted with regions of the rat and human VEGF-A promoter spanning the hypoxia
response element (HRE) and adjacent 3′ sites. In FDLE cultured at the PO2 of the fetal lung, FGF-10 relieved the
Spry2 interaction at the HRE region by promoting clearance of a 39 kDa form and this was accompanied by
histone-3 S10K14 phosphoacetylation, promoter de-methylation, hypoxia inducible factor-1α activation and
VEGF-A expression. This repressive characteristic of nuclear Spry2 was relieved in 16HBE14o- by shRNA
knockdown, and stable expression of mutants (C218A; C221A) that do not interact with the VEGF-A promoter
HRE region. We conclude that nuclear Spry2 acts as a molecular link which co-ordinates airway and vascular
growth of the cardiopulmonary system. This identiﬁes Spry2 as a contributing determinant of design optimality
in the mammalian lung.
1. Introduction
Weibel's latex cast of the human pulmonary airway and vascular
tree vividly illustrates the problem of optimality in anatomical design
and physiological function (the Symmorphosis debate; see image in
Glenny (2011)). We see an interwoven network of airway, arterial and
venous tubes branching at regular intervals with diminishing orders of
magnitude for up to ~17 generations, after which the morphogenic
programme diverges to create the alveoli and capillary bed of the re-
spiratory acinus. For all that this structure creates a low resistance/high
surface area for gas exchange, aerobic performance is constrained by
one fundamental design limitation: a single path for convective gas
movement to and from the blood-gas barrier. To be viable, this system
requires extraordinary scalar proportions (Glenny, 2011; Weibel, 1991)
which are generated by the interlinked branching morphogenesis pro-
gramme of the airway and vascular systems and it is this process which
ultimately sets the physiological boundaries for cardiovascular perfor-
mance. Peter Hochachka was a career-long contributor to the
Symmorphosis debate (e.g. (Hochachka et al., 1998)) and many of the
biochemical structure/function relationships he explored arise as
adaptive responses to the cardio-pulmonary system under challenge. In
recognition of his contributions to the ﬁeld, this original research ar-
ticle presents molecular evidence to support a role for Sprouty2 as a co-
ordinating link between the airway and vascular branching morpho-
genesis programmes. As such, we propose Sprouty2 as a key con-
tributing factor in establishing structure-function optimality in gas ex-
change systems.
Sprouty (Spry) proteins play a key role in organ development by
deﬁning the temporal and spatial patterning of growth events in folded
and branched organ structures. Early studies in Drosophila demon-
strated that knockout of the single Spry gene enhanced branching rate
of the tracheal airway (Hacohen et al., 1998) and later work in mam-
malian lung development established roles for a family of Spry homo-
logs (Spry1-4) in the regulation of airway tube elongation and
branching (de Maximy et al., 1999; Scott et al., 2010; Teﬀt et al., 2005;
Teﬀt et al., 2002; Teﬀt et al., 1999; Perl et al., 2003). The evidence
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suggests that Sprouty proteins participate in the morphogenic sub-
routines which determine fractal patterning in branched systems.
In lung development, airway branching is induced by mesoderm-
derived ﬁbroblast growth factor-10 (FGF-10) binding to the tyrosine
kinase receptor, FGFR2b, expressed in cells at the tip of the endodermal
airway tube. Downstream signalling through extracellular regulated
kinase 1/2 (ERK1/2) and the mechanistic target of rapamycin complex
1 (mTORC1) (Scott et al., 2010) induces outward growth toward the
FGF-10 signal and the duration of this event, a determinant of branch
length in the fractal patterning of the airway tree, is antagonised by
Spry2 (Teﬀt et al., 2002, 2005). We have expanded this model by
showing that Spry2 has the potential to co-ordinate vascular growth
with the airway branching programme by activating an mTORC-1–hy-
poxia inducible factor-1α (HIF-1α) complex which drives vascular en-
dothelial growth factor-A (VEGF-A) expression and secretion from the
airway endoderm (Land et al., 2014; Scott et al., 2010). Since pub-
lishing this work, however, it has emerged that a sub-population of
Spry2 resides in the nucleus (Ahn et al., 2010; Aranda et al., 2008),
raising the possibility that this regulator of airway branching could
inﬂuence nuclear events during the branching process. To determine if
Spry2 directly links the primary cues for airway (FGF-10) and vascular
(VEGF-A) growth in the pulmonary branching morphogenesis pro-
gramme, we tested the hypothesis that FGF-10 induces direct interac-
tion with between nuclear Spry2 and key elements of VEGF-A gene
regulation in fetal lung endodermal epithelium. Our results show that
Spry2 binds at several key positions in the 5′VEGF-A promoter and that
FGF-10 modulates this interaction to induce VEGF-A transcript ex-
pression. In addition to its well-established role as a regulator of re-
ceptor tyrosine kinase activity at the cell surface, we conclude that
Spry2 mediates epigenetic events in the nucleus and so co-ordinates
gene expression with airway and vascular growth factor signalling in-
tensity.
2. Materials and methods
2.1. Plasmids and antibodies
N-terminal FLAG and C-terminal Myc dual tagged Spry2 was con-
structed by sub-cloning full length Spry2 into pCMV-Tag-1 (Stratagene,
La Jolla CA, USA) and cysteine to alanine mutations were generated at
positions 218 and 221 to assess Spry2-DNA interactions. Non-genome
target control (TR20003) and shRNA vectors targeting human Spry2 in
pRS were originally purchased from Origene Technologies, Inc.
(Rockville, MD; Catalog number TR309130) and kindly supplied to us
by Drs P Yusoﬀ and G Guy (Proteos, Singapore). Stable Spry2 knock-
down in 16HBE14o- cells was achieved with the clone TI336513 (se-
quence ‘5-CTGAACAGAGACTGCTAGGATCATCCTTC-3’). Source, con-
centration and species of all antibodies used in this study are given in
Supplementary Table 1.
2.2. Cell culture and manipulation
Primary fetal distal lung epithelial cells (FDLE) were isolated from
gestation day 19 Sprague Dawley rat lungs at the pseudoglandular/
canalicular stage of development and maintained in polarised culture
on permeable supports as described (Land and Collett, 2001; Scott
et al., 2010). Culture of the human bronchial epithelial cell line
(16HBE14o- or “HBE” (Cozens et al., 1994)) was also as described
(Scott et al., 2010). Unless stated, cells were maintained at PO2
equivalent to the fetal lung in utero (3% O2) to conserve the FGF-10 and
HIF signalling pathway context (Scott et al., 2010). HBE stably trans-
formed with dual-tagged Spry2, Spry2-C218A or Spry2-C221A were
generated by puromycin selection of clonal cells.
2.3. Preparation of cytosolic, nuclear and chromatin-bound lysates
The full protocol is given in Supplementary Fig. 2 with initial lysis
procedures were conducted in a hypoxic chamber equilibrated to 3%
O2. Enrichment of Histone 3 (H3) conﬁrmed nuclear lysis.
2.4. Electrophoretic mobility shift assay (EMSA)
Protein interactions with the HIF DNA consensus sequence were
performed using [32P] radiolabelled oligonucleotides containing the
HIF response element (HRE) in the rat VEGF promoter (HRE under-
lined): 5′-TGC ATA CGT GGG CTT CCA CAG GTC-3′. The same sequence
with the HRE mutated to adenosines served as a negative control.
Nuclear protein binding and mobility shift were performed as before
(Land and Darakhshan, 2004) on 8% gels (37.5:1 acrylamide:bis-acry-
lamide). Supershift assays were performed by pre-incubating nuclear
protein with 1 μg of antibody on ice for 1 h before addition of probe.
Supershifts were resolved in 6% gels (29:1 acrylamide:bis-acrylamide).
2.5. Western blotting, VEGF ELISA and immunoﬂuorescence
Performed as described (Scott et al., 2010) using antibodies given in
the respective ﬁgure legend.
2.6. Quantitative real-time PCR
RNA was isolated using a Nucleospin RNA II Kit (Macherey-Nagel).
1 μg of RNA was reverse-transcribed using a Quantitect Reverse
Transcriptase Kit (Qiagen). qPCR was performed in duplicate on Rotor-
Gene Q cycler using a Rotor-Gene SYBR Green PCR Kit using Quantitect
Primer Assays (Qiagen). β2 microglobulin or 18S were used as house-
keeping genes for reference using the ΔΔCt method. Reaction eﬃciency,
standard curve regression and product melt characteristics were mon-
itored to ensure reaction ﬁdelity.
2.7. Chromatin immunoprecipitation assay (ChIP)
The full protocol including primer sets and chIP validation of Anti-
Spry2 (Abcam Ab50317) is given in Supplementary Fig. 2 and Table 2.
2.8. DNA methylation and high resolution melt analysis
Genomic DNA from wild-type or stably transformed HBE cells was
bisulﬁte converted using the Epitect Fast DNA Bisulﬁte Kit (Qiagen)
according to the manufacturer's instructions. Bisulﬁte-converted DNA
was adjusted to 50 ng/μl after a clean-up step and this volume was used
in conjunction with Epitect High Resolution Melting PCR (Qiagen) to
detect diﬀerences in DNA methylation at CpG sites located 145 bp 5′ to
the VEGF-A transcription initiation site (TIS) or 179 bp 3′ to this locus.
Methyl Primer Express® Software v1.0 (Applied Biosystems) was used
to select CpG methylation-speciﬁc primer sets. MS-HRM was performed
on a Rotorgene 6000 (Qiagen) and once each sample had reached the
plateau phase of the PCR a high resolution melting protocol was used to
expose methylation speciﬁc diﬀerences in the ampliﬁed DNA.
2.9. Statistics
Multiple comparisons were conducted using one way ANOVA with
post hoc signiﬁcance determined using Tukey's HSD. Values are
mean ± SEM with the number of observations reported in the legend
to each ﬁgure.
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3. Results
3.1. Spry2 is a nuclear protein in primary fetal airway epithelial cells
The ﬁrst aim of this study was to characterise nuclear Spry2 beha-
viour in relation to FGF-10 in primary FDLE and immortalised HBE
cells. Experiments were conducted at fetal (3% O2) as well as ambient
(21% O2) PO2 because fetal development occurs in an oxygen-restricted
environment and tissue oxygenation inﬂuences total cellular Spry2
stability (Anderson et al., 2011).
Immunoﬂuorescence in FDLE revealed that Spry2 nuclear abun-
dance was favoured at 3% O2 and resolved into plasma membrane and
nuclear populations when exposed to 0.1 μg·ml−1 FGF-10 for 6 h
(Fig. 1A). Nuclear protein western blots resolved Spry2 as a doublet at
35.4 ± 0.5 and 39.3 ± 0.6 kDa (n= 20) and shRNA knockdown in
FDLE and HBE conﬁrmed that both bands were products of the same
Spry2 transcript. FGF-10 induced a concentration-dependent clearance
of the 39 kDa form over 6 h with an EC50= 84 ± 18 ng·ml−1 in-
dependently of PO2 and no change was observed in the 35 kDa form
(Fig. 1Bi–iv). Dual tagged Spry2 expressed in HBE resolved in cytosolic,
nuclear soluble and chromatin enriched insoluble fractions Fig. 1C).
Immunoﬂuorescence shows native (Fig. 1Di–iii) and dual tagged ex-
pressed Spry2 (Fig. 1Div–vi) occurs in the nucleus in HBE and
associates with the spindle pole in anaphase cells suggesting a role in
planar cell division (Tang et al., 2011).
We investigated the diﬀerence in nuclear Spry2 protein mass by
determining if either form was inﬂuenced by phosphorylation, cleavage
or palmitoylation (Ding et al., 2007; Forrester et al., 2011; Scott et al.,
2010) (see Supplementary Fig. 1). Interventions in these processes af-
fected both forms equally and so we conclude that both Spry2 forms
retain conserved responses to pathways that are known to modify Spry2
activity.
To determine if the selected concentration range of FGF-10 induced
transcriptional activation we measured histone 3 (H3) phosphoacety-
lation at serine 10 and lysine 14 (H3-S10(P)K14(Ac)) (Islam and
Mendelson, 2008; Karmodiya et al., 2012). FGF-10 induced a con-
centration dependent increase in H3-S10(P)K14(Ac) phospho-acetyla-
tion which was matched by declining HDAC1-3 abundance as well as
the 39 kDa Spry2 form (Fig. 2).
3.2. Spry2 interacts with the HIF-1α Transcriptional Complex in FDLE and
HBE
The VEGF-A gene is transcriptionally regulated by HIF-1α and HIF-
2α and so we determined which isoform might interact with Spry2 at
the VEGF-A promoter. At fetal lung PO2, HIF-1, 2 and 3α proteins were
Fig. 1. Nuclear expression of Spry2 in FDLE. A. Immunoﬂuorescence shows Spry2 is nuclear in rat FDLE cells and this distribution is conserved irrespective of culture PO2 or FGF-10.
Image is representative of 4 independent preparations m – membrane, n – nucleus. Neg control, no primary antibody B. Spry2 resolves as 39 and 35 kDa in rat FDLE nuclear lysates; H3,
Histone 3 (i). FGF-10 induces clearance 39 kDa Spry2, (ii) Spry2 siRNA (rat FDLE, 250 pmol·ml−1) and stable shRNA (HBE) suppresses 35 and 39 kDa Spry2 abundance. (iii) Quantitation
of FGF-10 eﬀect upon 39 kDa 35 kDa Spry2 in FDLE, mean ± SEM, n= 6, *P < 0.05 relative to control. (iv) The eﬀect of FGF-10 upon 39 kDa Spry clearance is not altered by culture
PO2 does not alter irrespective of culture PO2, mean ± SEM, n= 6. C. Western blotting of cytosolic and nuclear Spry2 in 16HBE14o- (HBE) cells stably expressing dual tagged Spry2
(upper image). LiCor analysis simultaneously resolved N-terminal FLAG (red) and C-terminal Myc (green) epitope tags in cytosolic, nuclear-soluble and nuclear-insoluble fractions from
cells treated for up to 4 h in 0.1 μg·ml−1 FGF-10. Yellow in the merged image indicates co-localisation of the tags. The nuclear scaﬀold protein, p84, served as a loading control. Blots
representative of 4 independent experiments. D. Immunoﬂuorescence shows native (i–iii) and dual tagged expressed Spry2 (iv–vi) occurs in the nucleus in HBE cells and associates with
the spindle pole in mitotic cells (right). Images representative of 4 independent experiments; Abbreviations: m, membrane; n, nucleus; s, mitotic spindles; Ac Tub, Acetylated α-tubulin.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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detected in the nuclear fraction of FDLE cells and their abundance was
not signiﬁcantly altered by FGF-10 (Fig. 3A). However, VEGF-A mRNA
and protein expression were induced by 0.1 μg·ml−1 FGF-10 (Fig. 3B)
and electrophoretic mobility shift assays (EMSA) revealed enhanced
protein recruitment to the VEGF-A HIF response element (HRE)
(Fig. 3C). Supershift EMSAs revealed Spry2 and HIF-1α but not HIF-2α
or HIF-3α interacted at this complex (Fig. 3D). The VEGF-A promoter is
regulated by HIF-1α and HIF-2α and so, to corroborate our EMSA re-
sults, we explored the eﬀect of stable Spry2 shRNA knockdown in HBE
at fetal PO2 on transcript expression of VEGF-A, BNIP-3 (HIF-1α-regu-
lated) and CCND-1 (HIF-2α-regulated) (Preston et al., 2011). Spry2
knockdown signiﬁcantly increased VEGF-A and BNIP3 transcript
abundance with no overall eﬀect on HIF-1α mRNA expression. CCND-1
expression was signiﬁcantly suppressed in Spry2 knockdown cells
suggesting that the induction of VEGF-A is likely mediated by HIF-1α
(Fig. 3E).
3.3. Spry2 interacts with the VEGF-A promoter in FDLE
We hypothesised that nuclear Spry2 regulates the interaction be-
tween HIF-1α and the VEGF-A promoter during FGF-10 exposure and so
chromatin immunoprecipitation (chIP) was used to determine if Spry2
interacts with VEGF promoter elements. The commercial Spry2 anti-
body (Abcam ab50317) was validated for this purpose (Supplementary
Fig. 2) and used in combination with chIP grade antibodies against
histone 3 (H3; positive control), HIF-1α and CBP/p300 (indicator of
HAT binding and epigenetic gene activation). Parallel incubation with
non-immune IgG served as a negative control. ChIP primers were de-
signed against elements up to 1Kb upstream of the VEGF-A transcrip-
tion initiation site (TIS) (Supplementary Table 2 and Fig. 4). In FDLE,
nuclear Spry2 interacted with promoter elements spanning −944 to
−633 bp (contains the rat VEGF-A HRE), −661 to −384 bp (contains
the rat VEGF-A STAT-3 response element) and −403 to −124 bp
(contains several GC rich domains) (Fig. 4). Primers designed against
the transcription initiation site (TIS) failed to amplify in H3 positive
control samples and so no conclusive observations were made at this
location. Although chIP assays oﬀer only qualitative assessment of
protein-promoter interactions, we observed FGF-10 dependent inter-
action of nuclear Spry 2 and HIF-1α at the HRE-spanning region of the
promoter and induced binding of CBP/p300 at the adjacent region
spanning −661 to −384 bp. A strong, FGF-10-independent Spry2
signal was also observed at the most proximal region of the promoter
investigated (−403 to −124 bp).
3.4. Conserved residues in the Spry2 cysteine rich domain (CRD) are
necessary for interaction with the VEGF-A promoter
To determine how Spry2 might interact with DNA, bioinformatic
analysis (ExPASy PROSITE) was performed to search for possible con-
served DNA binding elements in the Spry2 protein sequence. This
analysis identiﬁed limited homology between amino acids 199 and 221
in the Spry2 CRD and a zinc ﬁnger RanBP2-type signature (W-x-C-x
(2,4)-C-x(3)-N-x(6)-C-x(2)-C; Entry Name: ZF_RANBP2_1, ExPASy
Accession number PS01358). The corresponding sequence in Spry2
(199WICxxxCxCxxxNxxxxxCxxC221) is approximated in the same region
between each of the other human Spry isoforms and is conserved be-
tween species (Fig. 5A). To determine if this region alters Spry2 inter-
action with the HIF consensus region of the human VEGF-A promoter,
we mutated cysteines to alanines at position 218 or 221
(199WICxxxCxCxxxNxxxxxC/AxxC/A221), created stable HBE cell lines
and performed ChIP assays using primers designed to amplify−1089 to
−882 bp of the human VEGF-A promoter (Human VEGF-A HRE lies at
−975 to−968 bp, (Pagès and Pouysségur, 2005)). ChIP was performed
using anti-Spry2 or anti-myc antibodies to resolve the c-terminal epi-
tope Myc tag of Dual tagged Spry2. IgG and H3 controls were per-
formed as before. Both antibodies resolved interaction of wild-type
(WT) Spry2 with this region of the VEGF-A promoter which was di-
minished or absent in cells stably expressing either C218A or C221A
Spry2 mutants (Fig. 5B). Neither HIF-1α stability nor Spry2 nuclear
abundance were altered by these treatments but C218A and C221A
mutation signiﬁcantly enhanced H3 S10K14 phosphoacetylation and
raised VEGF-A expression compared to cells wild-type Spry2 trans-
formed cells (Fig. 5C and D). These events occurred without detectable
variation in the cellular distribution of wild-type, C218A or C221A
Spry2 or endogenous ERK1/2 activity (Supplementary Fig. 3) sug-
gesting that the mutant forms did not alter the non-nuclear function of
Spry2. Thus, our data show that Spry2 is present in the nucleus of
primary fetal, and immortalised adult, airway epithelial cells, interacts
Fig. 2. FGF-10 induces histone modiﬁcation in FDLE
and correlates with the decline in 39 kDa Spry2. A.
FGF-10-evoked decline in 39 kDa Spry2 in nuclear
and cytosolic fractions corresponds with increased
Histone 3 S10(P)K14(Ac) phosphoacetylation and
decreased nuclear abundance of HDAC1-3. B. (i)
Relationship between H3 S10(P)K14(Ac) phosphoa-
cetylation and FGF-10 concentration and (ii) 39 kDa
Spry2 abundance (FGF-10 concentration (μg·ml−1)
shown next to symbols). Values are Mean ± SEM,
n= 4; *P < 0.01 relative to control.
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with discrete regions of DNA to inﬂuence gene expression (VEGF-A in
this case) and that this interaction requires cysteine residues C218 and
C221 in the Spry2 CRD.
3.5. Spry2 knockdown or CRD mutation diminishes CpG island methylation
in the VEGF-A promoter
Spry2 knockdown and mutation of CRD residues C218 and C221
augment VEGF-A expression suggesting a role in silencing gene activity.
CpG island methylation is an important part of this regulation and the
region surrounding the transcriptional initiation site (TIS) of the human
VEGF-A gene is rich in potential CpG methylation sites (Fig. 6A). We
therefore used the Methylation Speciﬁc High Resolution Melt analysis
(MS-HRM) method (Candiloro et al., 2011) to investigate the eﬀect of
FGF-10, Spry2 knockdown and Spry2 CRD mutation upon the methy-
lation of CpG sites the VEGF-A TIS.
Two primer sets designed to detect methylated or unmethylated
DNA sequences were used to analyse the methylation status of a region
spanning −143 to 0 bp upstream of the VEGF-A site (5′VEGF-A TIS
containing 17 CpG sites) and a second region spanning +13 to
+199 bp downstream to the VEGF-A TIS (3′VEGF-A TIS containing 16
CpG sites). 20 ng of bisulﬁte converted DNA was ampliﬁed through
40 cycles of qPCR followed by HRM. Commercial methylated and un-
methylated DNA served as controls.
5′VEGF-A TIS methylated primers resolved melt-peaks in the
0 μg·ml−1 FGF-10-treated and shRNA control samples that corre-
sponded to the position of the 100% methylated control indicating
extensive methylation of this region of the VEGF-A promoter.
Treatment with FGF-10 or knockdown of Spry2 induced a leftward shift
toward the position of the unmethylated control peak (Fig. 6B). Primers
designed to detect unmethylated DNA within this region revealed that
most of the DNA in this region occurs as a heteroduplex suggesting
diﬀerential methylation occurs between complementary DNA strands,
however, both FGF-10 treatment and Spry2 knockdown raised the
proportion of the DNA melt curve that fell under the unmethylated
control peak. In contrast, the vast majority of DNA ampliﬁed from the 3′
Fig. 3. FGF-10 does not alter HIFα subunit stability but increases
VEGF-A expression and protein recruitment to the VEGF-A HRE in
FDLE. A. Western blot of nuclear HIFα proteins, Spry2 and Histone 3
(H3) from FDLE exposed to increasing concentrations of FGF-10.
CoCl2 (100 μM, 16 h), positive control, representative of 4 in-
dependent experiments. B. mRNA and protein abundance of VEGF-A
exposed to FGF-10 measured by qPCR and ELISA, mean ± SEM,
n= 4, *P < 0.05. C. EMSA showing retarded migration of [32P]-
VEGF-A HRE probe incubated with 10 μg of nuclear lysate from FDLE
cells treated with FGF-10 as indicated. Mutant probe (Mut) shows
non-speciﬁc binding; Free probe, unincorporated excess probe;
dotted line shows position of band at 0 μg·ml−1.FGF-10 D. Supershift
EMSA showing decreased mobility of bands incubated with anti-
bodies (1 μg) against Spry2 and HIF-1-3α. Non-immune IgG, control.
E. qPCR analysis showing eﬀect of stable Spry2 knockdown in HBE
cells (Spry2 shRNA) maintained at fetal PO2 upon transcript abun-
dance of Spry2, HIF-1α VEGF-A (regulated by HIF-1α and HIF-2α)
BNIP3 (regulated by HIF-1α) and CCND1 (regulated by HIF-2α).
Values are mean ± SEM, n= 4, *P < 0.05.
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Fig. 4. Nuclear Spry2 interacts with 5′ elements in the rat
VEGF-A promoter. FDLE cells were incubated at fetal PO2 in the
absence or presence of FGF-10 at the given concentrations. ChIP
was performed using primers designed to amplify 5′ promoter
elements as indicated in the diagram (right). Sequence align-
ments are to scale and are for the rat VEGF-A promoter; the
position of the HIF consensus site is shown. Arrow at 3′ end
indicates position of classical transcriptional initiation site
(TIS). Result is representative of at least 4 independent ex-
periments.
Fig. 5. A region within the Spry2 cysteine rich do-
main (CRD) is necessary for Spry2 to interact with a
region spanning the human VEGF-A HIF consensus
site. A(i.) Sequence alignment of amino acids
199–221 in human Spry2 with Spry1, 3 and 4 with
residues in Spry2 showing homology with the
RanBP2 Zn2+ ﬁnger signature given in bold and un-
derlined. (ii) Species conservation of the Spry2 se-
quence given in (i). B. ChIP assay against a region of
the human VEGF-A promoter spanning the HIF con-
sensus site. Stable HBE cell lines were generated that
expressed either empty vector, wild-type Spry2
(Spry2-WT), Spry2-C218A or Spry2-C221A. ChIPs
performed with Anti-Spry2 or Anti-Myc (C-terminal
epitope) were performed in independent samples (2
each). C. HIF-1α and Spry2 nuclear abundance are
unaﬀected but Histone-3 S10K14 phosphoacetylation
is enhanced in stable HBE cells expressing C218A or
C221A Spry2 mutants. *P < 0.05 relative to Spry2-
WT, n= 5 D. qPCR showing augmented VEGF-A
mRNA expression in HBE cells bearing Spry2-C218A
or Spry2-C221A mutants. Values are mean ± SEM,
n=4, *P < 0.05 relative to Spry2-WT.
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TIS region resolved as un-methylated DNA and was not aﬀected by any
of the treatments. Taken together, these results indicate that FGF-10
treatment or Spry2 shRNA knockdown results in de-methylation of CpG
residues in the 5′VEGF-A TIS. A similar analysis of the 3′VEGF-A TIS
indicated that, although heterogeneous DNA methylation was evident
with the methylated primer sets, the majority of CpG sites in this region
remained unmethylated.
Mutation of C218 and C221 residues in the CRD region of Spry2 also
altered DNA methylation patterns in the 5′VEGF-A TIS region (Fig. 6C).
Although no shift in the methylated peak position was observed, C218A
or C221A mutation increased the proportion of the unmethylated
primer product under the peak area of the unmethylated control. Once
again, very little DNA methylation was detected in the 3′TIS VEGF-A
region. Taken together with the loss of DNA interaction and increased
VEGF-A expression, the mutation of these residues appears critical for
Spry2 DNA interactions and epigenetic regulation of gene expression.
4. Discussion
The semi-fractal organisation of the pulmonary tree, as beautifully
illustrated by Weibel's latex cast, implies the presence of a molecular
branching periodicity regulator which, 1) sets the duration of tubular
elongation, 2) determines the position of each branch point, 3) re-ca-
librates branching subroutines at each daughter generation, 4) co-or-
dinates all of these processes between airway and vascular systems and
5) determines the point at which the branching programme diverges to
form the gas exchange surfaces. Here, we report that Spry2, a conserved
regulator of branching morphogenesis across species, is present in the
nucleus of airway cells derived from the fetal lung, is regulated by the
primary inducer of airway outgrowth, FGF-10, and represses the
Fig. 6. Manipulation of Spry2 function by FGF-10,
shRNA knockdown or CRD mutation promotes de-
methylation of the regions ﬂanking the VEGF-A
TIS in HBE cells. A. Sequence of the region
ﬂanking the human VEGF-A TIS (grey). Putative
CpG methylation sites are highlighted (under-
lined) B. High resolution melt (HRM) analysis of
VEGF-A promoter methylation. Control melt
curves for 5′ and 3′ VEGF-A ﬂanking sequences
are shown at the top and were generated using
100% methylated (solid line) or 100% non-me-
thylated DNA (dashed line). Corresponding melt
curves for FGF-10 treated samples and control
versus Spry2 shRNA are shown beneath respec-
tively. Solid line: primers against methylated
DNA; Dashed line: primers against unmethylated
DNA. Leftward shift in HRM curve (arrows) in-
dicates lowered incidence of CpG methylation.
Peaks in heteroduplex region suggest non-uniform
CpG methylation between VEGF-A alleles. C. As
for panel A but relationship is shown for HBE cells
stably expressing control (wild-type) Spry2, Spry2
C218A and Spry2 C221A. Graphs are re-
presentative of 3 independent experiments.
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activity of the main inducer of VEGF-A transcript expression, HIF-1α.
Using chIP and DNA methylation analysis, we show that Spry2 interacts
directly with regulatory regions of the VEGF-A promoter and that its
knockdown induces demethylation and subsequent expression of VEGF-
A transcripts and protein. Taken as a whole, we argue that Spry2 has a
central role to play in the molecular co-ordination of airway and vas-
cular branching periodicity. As such, it is an important contributor to
design optimality in the cardio-pulmonary system.
The mechanisms which underpin nuclear Spry2 signalling require
evaluation. The electrophoretic migration of Spry2 as a doublet is fre-
quently reported in the literature (see, for examples (Anderson et al.,
2011; Aranda et al., 2008; Fong et al., 2003; Impagnatiello et al., 2001;
Scott et al., 2010)) and a number of processes could account for this
diﬀerence in molecular weight. Spry2 is post-translationally modiﬁed
by phosphorylation and palmitoylation (Impagnatiello et al., 2001) and
is also ubiquitylated through its interaction with E3 ligases such as Cbl,
SIAH2 and NEDD4 (reviewed Edwin et al., 2009). Although our results
show evidence that Spry2 is palmitoylated and that its protein abun-
dance is stabilised by kinase inhibition, neither eﬀect accounted for the
molecular mass diﬀerence between the two forms. One possibility,
untested here, is that the 39 kDa form represents a mono-ubiquitylated
form of Spry2 that is primed to respond to growth factor signals. Lysine
monoubiquitylation has been linked to protein traﬃcking between
compartments and organelles and is distinct from polyubiquitylation in
that it does not necessarily result in protein degradation. In some cir-
cumstances, this process promotes transcription factor nuclear trans-
location and DNA binding (e.g. FOXO4 (van der Horst et al., 2006)) and
within the nucleus itself, histone monoubiquitylation governs the epi-
genetic status of DNA (Ouni et al., 2011). Given that Spry2 interacts
with ubiquitin ligases and is known to translocate between diﬀerent
compartments of the cell, it is possible that the molecular weight dif-
ferences are driven primarily by monoubiquitylation and secondarily
by polyubiquitylation that controls the overall abundance of the Spry2
protein.
Repression of vascular signalling by Spry proteins has been de-
scribed in a number of models of development and disease and un-
derpins the role of these proteins as critical mediators of vascular sta-
bility. For example, Spry2 or 4 knockout in mice causes malformation
of cardiovascular structures that is lethal at birth and shRNA knock-
down of these proteins in a murine model of hind-limb ischemia-re-
perfusion injury drives angiogenesis following ischemic injury
(Taniguchi et al., 2009). In lung development and wound repair, high
Spry2 expression levels correlate with vascular atrophy (Lazarus et al.,
2011; Wietecha et al., 2011). These eﬀects are explained, at least partly,
by Spry2-mediated repression of angiogenic RTK signalling along the
ras/MEK/ERK1/2 pathway, however, to our knowledge, no study has
investigated the possibility that Spry2 may directly inﬂuence the pro-
cess of vascular gene activation in the nucleus. Our results support a
role for Spry2 as a repressor of transcriptional events that control
vascular gene expression and that RTK signalling (in this case, activa-
tion of FGFR2b by FGF-10) relieves this by clearing the 39 kDa form of
Spry2 from the nucleus.
HIF-1αmediates vascular gene expression in the early stages of lung
development and so we tested the hypothesis that repression of HIF
activity and VEGF-A expression was mediated by interaction between
Spry2 and the VEGF-A promoter to alter one of, i) HIF-1α recruitment
to the HRE, ii) CBP/p300 histone acetyl transferase recruitment or iii)
DNA methylation status. We found that Spry2 interacted to varying
extents with regions of the rat VEGF-A promoter spanning −944 bp to
−142 bp. Reliable resolution of protein-DNA interactions could not be
detected at sites ﬂanking the transcription initiation site (TIS) because
the high GC content this region. Notably, however, we observed a FGF-
10-responsive interaction in the region of the promoter that spanned
the HRE and apparently constitutive interactions in neighbouring
downstream regions that include response elements for STAT3 and
SP1/SP3. In FDLE cells, the loss of Spry2-DNA interaction that occurred
with FGF-10 treatment corresponded with a transient increase in the
HIF-1α-binding at this site and also increased VEGF-A expression. This
diﬀered in HBE cells, however, where stable knockdown of Spry2
produced similar increases in VEGF-A expression but did not alter HIF-
1α or CBP/P300 binding to this region. In FDLE, the CBP/p300 inter-
action was detected in the neighbouring downstream site and increased
with the decline in Spry2 DNA binding. Since STAT3 interacts with this
site and is known to modulate HIF-1α signalling and VEGF-A expression
(Xu et al., 2005) we investigated if the activity of this transcription
factor was altered by changes Spry2 abundance. We found no sig-
niﬁcant activation of STAT3 with any of these treatments (data not
shown) and so excluded this pathway from further investigation. In
HBE cells, our investigation of the human VEGF-A HRE region revealed
a number of important functional aspects of the Spry2 interaction at
this region. Firstly, we found that Spry2 knockdown abolished the
oxygen dependence of HIF-1α signalling and profoundly raised both
HIF-1α and CBP/p300 interaction with this site. This was accompanied
by increased HIF-1α activity in high oxygen conditions. Secondly, we
showed that the interaction of Spry2 at this site depended upon con-
served cysteine residues at position 218 and 221 since mutation of ei-
ther residue resulted in loss of Spry2 interaction and increased HIF-1α
activity and VEGF-A expression. These residues were identiﬁed from a
PROSITE scan of homologous Zn2+ ﬁnger domains and although we did
not investigate if Zn2+ was necessary for the Spry2-DNA interaction, it
is possible that this site acts as a redox centre that mediates Spry2 in-
teraction with other macromolecules, including DNA. Indeed the high
level of conservation of these residues from insects to mammals and
between mammalian Spry isoforms suggests that they are critical
mediators of Spry2 function. Taken together, however, these results
suggest that Spry2 functions as a repressor of VEGF-A expression,
possibly by controlling the recruitment of HIF-1α and CBP/p300 tran-
scription co-activators to the VEGF-A promoter.
The 5′ TIS region of the VEGF-A promoter is ﬂanked by GC rich
sequences whose methylation may regulate transcription of the VEGF-A
gene. We were unable to reliably detect Spry2 interactions in this re-
gion using ChIP and so high resolution melt analysis (Candiloro et al.,
2011; Xu et al., 2005) was used to determine if CpG methylation was
altered by FGF-10, Spry2 shRNA or Spry2 C218/C221 mutation. H3-
S10/K14 phosphoacetylation blocks methylation of H3-K9, a marker of
gene condensation and lowered gene expression (Candiloro et al.,
2011), and was dose-dependently increased by FGF-10. In keeping with
this, we detected methylated and heteroduplex (methylated/un-
methylated alleles) in all samples and found that FGF-10 and Spry2
knockdown resulted in a leftward shift in melting proﬁle that is con-
sistent with a de-methylation of the VEGF-A promoter in this region.
Methylated DNA was not detected in the downstream 3′TIS region.
Similarly, stable mutation of cysteines 218 and 221 produced a leftward
shift in heteroduplex methylation compared to wild-type Spry2. As a
whole, this data suggests that the presence of Spry2 in the nucleus is
associated with VEGF-A promoter methylation and events which dis-
rupt its function (FGF-10, shRNA C218, C221 mutation) result in loss of
methylation and induction of the gene.
Fig. 7 places these data into context with the mechanisms which link
Spry2 to the control of vascular gene signalling in the fetal lung. In the
absence of FGF-10, hypoxic induction of the VEGF-A gene is held in
check by interaction of the 39 and 35 kDa forms of Spry2 with regions
of the 5′VEGF-A promoter over several transcriptional regulation sites
including the HRE. FGF-10 relieves this interaction in two ways. Firstly,
our previous results demonstrate that loss of 39 kDa Spry2 in the cy-
tosol promotes HIF-1α activation by favouring mTORC-1-dependent
interaction between HIF-1α and its transcriptional co-activator, CBP/
P300 (Land et al., 2014; Scott et al., 2010). Secondly, the present data
adds to this model by showing that loss of 39 kDa Spry2 from the nu-
cleus promotes de-condensation of DNA and so facilitates growth factor
dependent VEGF-A gene expression. These results add to the established
role of Spry2 as a modulator of receptor tyrosine kinase signalling, and
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important contributor in disease (Edwin et al., 2009), by demonstrating
that this protein co-ordinates nuclear gene activation events with pre-
vailing growth factor conditions. In comparative terms, the scene is set
to expand investigation of sprouty proteins and related forms (e.g.
SPREDs) to understand the evolutionary origins of branching morpho-
genesis programmes, from the excretory canal cell of nematodes to
complex structures including the human brain.
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